Evidence of a significant pharmacovigilance signal on the risk of PPI-induced lupus erythematosus
Approximately 10% of lupus erythematosus (LE) is drug-induced.
Proton Pump Inhibitors (PPIs) are one of the most prescribed drug classes worldwide and their involvement in the occurrence of induced LE was suggested. We conducted a disproportionality analysis in the French and worldwide pharmacovigilance databases, which identified 49 cases of lupus notified as associated with the use of PPIs, with a predominance of subacute skin forms. It is noteworthy that 50% recovered without specific treatment when PPIs were stopped. The disproportionality study showed an association between PP exposure and the occurrence of induced lupus (systemic and cutaneous) in the main analysis and in all sensitivity analyses.
Early recognition of these PPI-induced lupus is necessary, as PPI discontinuation is associated with regression of LE in 50% of cases.
This article was published in JAMA Dermatology.
Proton Pump Inhibitors Associated With Drug-Induced Lupus Erythematosus.
Bataille P, Lebrun-Vignes B, Tubach F, Aroux-Pavard M, Philibert C, Chasset F, Barbaud A.JAMA Dermatol. 2022 Oct 1;158(10):1208-1210. doi: 10.1001/jamadermatol.2022.2421.